About 600 AstraZeneca US Sales Jobs Go as Its $1.5 Billion Savings Plan Kicks In
About 600 AstraZeneca US respiratory and immunology sales jobs are gone, Bloomberg reports, under a $1.5bn savings plan. What it means for pharma sales reps.

AstraZeneca has cut about 600 jobs from its respiratory and immunology commercial teams in the US, Bloomberg News reported on Friday, Nov. 13, citing people familiar with the matter. The figure is Bloomberg's, not the company's, and AstraZeneca declined to comment. Some affected staff are expected to be reassigned within the company. Bloomberg tied the cuts to a savings plan the drugmaker set out in late October. For Metaintro readers in pharma sales, this guide covers what was cut, the company's position on jobs, where AstraZeneca is still adding people, and what drug sales roles pay.
What Has Been Reported About the AstraZeneca Sales Cuts?
In the Bloomberg account, the roles include marketing jobs in the respiratory and immunology businesses, and some were selling two asthma medicines, Breztri (budesonide, glycopyrrolate, and formoterol fumarate) and Airsupra (albuterol and budesonide).
AstraZeneca, which declined to comment, has not said how many staff will be reassigned, which territories are affected or what severance it is offering.
Why Are the Reported Sales Cuts Coming Now?
The cuts follow the UK-based drugmaker's late-October announcement of that savings plan, which was published in its 9M and Q3 2026 results release on 30 October 2026. They also come as chief executive Pascal Soriot seeks to reassure investors that the company can meet its target of $80 billion in annual revenue by 2030.
The respiratory and immunology portfolio accounted for 16% of its third-quarter revenue at $2.5 billion, and in the first nine months of 2026 Respiratory & Immunology grew +10% at constant exchange rates, so the cuts land in a unit that is still growing.
Total revenue for the whole company in the first nine months was $46.9bn, with growth in Oncology, R&I and Rare Disease offsetting headwinds from Farxiga and Brilinta loss of exclusivity and volume-based procurement in China. Third-quarter revenue came in at $16.2 billion, a 7% jump over the same period a year before, a Leerink Partners note cited by BioSpace said. Across the first nine months, total revenue rose 7% and Core EPS 14%, along with approvals for four new medicines and 12 positive Phase III programme readouts in the year to date.
What Does the Reshaping for Sustainable Growth Plan Actually Say?
AstraZeneca initiated the Reshaping for Sustainable Growth (RSG) programme to create additional capacity to invest behind its pipeline and transformative technologies.
Over the next three years, the programme will redeploy resources and strengthen capabilities across AstraZeneca's existing business and therapy areas. The savings will continue to be reinvested back into the Company, principally in the pipeline.
The company anticipates activities to be essentially complete by the end of 2029. It has more than 180 pipeline projects driving its next wave of growth and scientific innovation.
In the third quarter, Core SG&A was 24% of Total Revenue (25% for 9M 2026), a slightly larger share than Core R&D at 22% of Total Revenue (23% for 9M 2026), and one driver of SG&A was investment to support ongoing and future launches.
The RSG programme is expected to cost up to $2.0bn in one-time restructuring costs and deliver $1.5bn in annualised pre-tax run-rate benefits, according to AstraZeneca's Q3 results release.
Did AstraZeneca Say Its Headcount Would Fall?
No. The company does not expect total headcount to shrink. In the words of chief financial officer Aradhana Sarin at the launch, "Overall we do expect that the company will continue to grow, we are not expecting to shrink the headcount."
In Sarin's description, the plan has "areas where we are upskilling employees, reskilling employees, hiring new people, skills and new technology areas, and there will also be areas where we are reducing slightly or reorganising slightly." She described the programme as widespread, not aimed at one location or business unit.
Soriot framed it the same way on the results day call with media, saying "It's more reallocation of resources across the pipeline and across the world." Sarin added that the aim was "to create capacity in the organization to absorb the growth that we're expected to have without necessarily, you know, growing all through headcount."
In the BioSpace story from launch day, no layoffs are expected, and by the account of executives the program will impact all areas of the business. At launch the company declined to provide details on where the savings would come from and whether jobs would be impacted.
Does Technology Play a Part in the Savings Plan?
Yes, and it applies across the company. Alongside retraining certain employees, AstraZeneca will hire new people or employ technology for efficiencies. Sarin's description of the plan also has "elements of incorporating technology within all our processes."
The newest US labs, at the Kendall Square centre, have ten floors of interconnecting laboratories built around technologies that integrate robotics, continuous automation, and agentic AI. The building is a 570,000 square foot, 18 story site at 290 Binney Street, and it joins the company's other US-based global strategic research centre in Gaithersburg, Maryland.
How Big Is AstraZeneca's Workforce in the US and Worldwide?
AstraZeneca employs 100,000 workers globally, of which around 10,000 are based in the UK. The US is the larger base, where the workforce exceeds more than 25,000 people and supports nearly 100,000 jobs overall across the country.
Those US staff work across a coast-to-coast footprint of 24 R&D, manufacturing, commercial and corporate sites. The US was also the company's largest market by sales in its November 2025 Maryland release.
Where Is AstraZeneca Still Adding Jobs in the US?
The company has opened new labs and plans new plants, and its new research centre in Kendall Square, Cambridge, Massachusetts, opened on 5 October 2026. Together with its genomic medicine site at 100 Binney Street, it will be home to nearly 2,000 researchers and scientists. That figure covers the research staff of both sites, and AstraZeneca has not given a count of new roles among them. Respiratory work is part of that plan, as leading experts there will deliver novel treatments to people struggling to live with diseases such as COPD, obesity and metabolic disease, breast cancer and rare diseases.
AstraZeneca is investing more than $1 billion in Massachusetts, a sum that will grow AstraZeneca's workforce in Massachusetts by over 50%, a projection rather than open vacancies. That spending is part of its broader US investment of $50 billion.
Manufacturing is the other growth area. A Maryland expansion unveiled in November 2025 will support 2,600 jobs across the two sites in the state including the retention of local roles, construction activity, and the creation of 300 highly skilled jobs. The Frederick biologics expansion is expected to be operational in 2029, so the new plant roles there are future openings. That Frederick expansion alone will create 200 highly skilled jobs and 900 construction roles. The new clinical manufacturing site in Gaithersburg will create an additional 100 jobs, retain 400 roles and support a further 1,000 construction-related jobs.
For a laid-off sales rep, these are mostly science and plant roles. They show where the company's money is going, but they are not a like-for-like landing spot for someone whose job was calling on clinics.
You don't spend one and a half billion dollars without creating jobs, CEO Pascal Soriot said on the third-quarter earnings call with media, according to the BioSpace report on the savings plan.
Is Respiratory Still a Growth Area for AstraZeneca?
Yes, on the company's own record. Since its previous results, Breztri won approval for asthma in the EU and Japan, based on the KALOS and LOGOS trials, as listed in the regulatory approvals table of its Q3 results release. Tozorakimab in COPD was submitted or accepted for review in the US and Japan, as the submissions table in the same release shows.
Soriot also pointed to possible deals in oncology, cardiovascular, rare disease, immunology and respiratory disease.
For anyone who wants to stay in respiratory sales, that record shows recent approvals and filings in the therapy area, even after the Bloomberg account of cuts to its US commercial teams.
What Do Pharmaceutical Sales Reps Earn, and Is the Field Hiring?
Federal data groups drug reps with other sellers of technical and scientific products, a category that spans agricultural and mechanical equipment to computer and pharmaceutical goods. For that group, the median annual wage for sales representatives, wholesale and manufacturing, technical and scientific products was $104,920 in May 2025.
The pay range in that category is wide, as the lowest 10 percent earned less than $52,600, and the highest 10 percent earned more than $200,440. The category held about 292,000 jobs in 2025. Reps who sell other goods earn less, as the median annual wage for sales representatives, wholesale and manufacturing, except technical and scientific products was $72,080 in May 2025, and that larger group held about 1.3 million jobs in 2025. The work often comes with miles, since some wholesale and manufacturing sales representatives have large territories and travel considerably. Reps who are not product experts frequently team with a technical expert.
Overall employment of wholesale and manufacturing sales representatives, a wider group that also includes nontechnical sellers, is projected to show little or no change from 2025 to 2035, yet about 123,400 openings for wholesale and manufacturing sales representatives are projected each year, on average, over the decade, most of them expected to replace workers who move to other occupations or leave the labor force, such as to retire.
For products that are scientific or technical, sales representatives typically need at least a bachelor's degree. Promotion often means an assignment to a larger account or territory, for which commissions are likely to be greater, and those with good sales records and leadership ability may advance to sales manager, sales supervisor, district manager, or vice president of sales. Most employers use a combination of salary and commissions or salary plus bonuses, a pay mix that also applies to outside sales representatives who cover field territories.
The hours are long, as most wholesale and manufacturing sales representatives work full time and many work more than 40 hours a week. Many companies have formal training programs for beginning wholesale and manufacturing sales representatives, and while it is not required, some wholesale and manufacturing sales representatives choose to earn professional certification.
What This Means for Pharma Sales Reps, and What Should You Do Next?
A company can expect no fall in total headcount and still cut roles in one unit, and that is what AstraZeneca's own words and the Bloomberg story together describe. The company is not expecting to shrink the headcount, yet Bloomberg News has reported cuts in its US respiratory and immunology commercial teams, which the company has not confirmed. Net figures protect the total, not your territory.
- If you were affected, ask about an internal move first. The plan is meant to redeploy resources. Ask which open roles you can apply for, and get the answer in writing.
- Follow the money inside the company. The savings go principally in the pipeline, and the plan, in Sarin's description, includes hiring new people alongside upskilling and reskilling.
- Sell your therapy-area depth, not just your quota. Respiratory is still a growth area, as the approvals and filings above show. Put your asthma and COPD knowledge at the top of every application to other respiratory drug makers.
- Look across the wider technical sales field. The federal pay figures above cover every rep who sells technical and scientific products, and the openings figure covers all wholesale and manufacturing reps, so search beyond pharma brands too.
Field sales resumes are built on results, and the sales representative resume guide covers bullet wording for rep roles.
Lacey Kaelani, Metaintro's CEO, puts it this way: A savings plan tells you where a company is moving its money. If your role sits on the side being trimmed, start building a bridge to the side being funded before anyone asks you to.
Related Articles
- How to Job Search With AI After a Layoff
- Laid Off by Amazon? Some Former Workers Are Being Asked Back for AI and Cloud Roles
- Biopharma IT Jobs Face Fiercest Competition
- Arvinas Announces Major Layoffs Amid Biotech Industry Challenges
- Best Jobs for a Career Change and Why Transferable Skills Matter More Than a New Degree
- Internal Interview Thank-You Email, What to Send After a Promotion or Transfer Interview
- Why Meta Backed Off Moving Employees Into AI Training Roles
- Which Healthcare Jobs Are Exposed as UnitedHealth Turns to AI Bots
- Tmunity Therapeutics Faces Layoffs Following Gilead Acquisition
People Also Asked
Q: How many jobs did AstraZeneca cut in the US?
A: AstraZeneca cut about 600 jobs from its respiratory and immunology commercial teams in the US, Bloomberg News reported, citing people familiar with the matter. AstraZeneca declined to comment.
Q: What is AstraZeneca's Reshaping for Sustainable Growth programme?
A: It is a three-year plan that is expected to cost up to $2.0bn in one-time restructuring costs and deliver $1.5bn in annualised pre-tax run-rate benefits, with the savings reinvested mainly in the drug pipeline.
Q: Will AstraZeneca reduce its total number of employees?
A: Chief financial officer Aradhana Sarin said the company does not expect it to, "we are not expecting to shrink the headcount," while also saying some areas would be reduced or reorganised slightly.
Looking for your next opportunity? Metaintro brings together 50M jobs in one place. Create a free profile and start your search today.

For job seekers
Spend your time on the work, not the search.
Free to start. No résumé needed. Real jobs, picked for you, by text.
- MatchCompare live roles against your current evidence.
- PositionTurn proof projects into role-specific applications.
- ImproveUse market feedback to keep the skill plan current.





